IMPACT OF FUNDED RESEARCH

To date we have awarded over $4 million in research grants. Below you will find a description of the projects we are accelerating.

2007 Grants:

"Potential Role of FCRL2 as a Surrogate Marker of IgV_H Mutation in CLL"
Randall S. Davis, M.D.
University of Alabama at Birmingham

"Pre-Clinical Studies of PEITC as a Novel Agent for Treatment of CLL”"
Peng Huang, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center

"Novel NF-_κB Inhibitors for CLL Treatment"
John C. Reed, M.D., Ph.D.
Burnham Institute for Medical Research

"Genetic and epigenetic pathways in CLL"
Stephan M. Tanner, Ph.D.
The Ohio State University

"Identification and Characterization of Tumor Initiating Cells in Chronic Lymphocytic Leukemia"
Francisco Vega M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center

2006 Grants:

Biology

"CD38 and the fate of CLL cells: innocent bystander or culprit?"
Silvia Deaglio M.D.
University of Torino, Medical School

"Role of STAT-3 in Serine Phosphorylation"
Zeev Estrov, M.D.
University of Texas M.D. Anderson Cancer Center

"Detailed analysis of cellular response mechanisms after chemotherapy and antibody treatment in biological CLL subgroups"
Stephan Stilgenbauer, M.D.
University of Ulm

Immunology

"Global phenotype profiling of chronic lymphocytic leukemia"
Stephen Mulligan, M.B., B.S., Ph.D.
University of Sydney

Genetics

"Proteomic characterization of activation induced TCL1-complexes and their targeting as a therapeutic strategy in CLL"
Daniel Jones, M.D., Ph.D
University of Texas M. D. Anderson Cancer Center

"Transcriptional activation to target CLL"
Deepa Sampath, Ph.D.
University of Texas M. D. Anderson Cancer Center

Therapy/Prognostic

"Identifying Therapeutic Targets by Profiling DNA repair in CLL"
Alexander Dobrovic, PhD
Peter MacCallum Cancer Centre

"Targeting Src-family kinases (SFKs) by membrane-permeant peptides"
Michael Hallek, M.D.
University Cologne (Germany)

"Identification of Germline Variants Influencing the Clinical Expression of Chronic Lymphocytic Leukemia"
Richard Houlston, M.D., Ph.D.
Institute of Cancer Research (United Kingdom)

"Application of gold nanoparticles in the treatment of B-Chronic Lymphocytic Leukemia (CLL)?"
Priyabrata Mukherjee, Ph.D.
Mayo Clinic

"ZAP 70 methylation: a new prognostic marker in CLL"
David Oscier, M.D.
Royal Bournemouth Hospital (United Kingdom)

"MicroRNAs targeting TCL1 as therapeutic agents for B-CLL"
Yuri Pekarsky, Ph.D.
Ohio State University

2005 Grants:

Biology

"Microenvironmental regulation of survival and growth of B lymphocytes from patients with Chronic Lymphocytic Leukemia (CLL)."
Jan Burger, M.D., Ph.D.
University of Texas M.D. Anderson Cancer Center

Supported Care

"Monitoring of Innate Cellular Immune Response in Chronic Lymphocytic Leukemia- A Pilot Study to Assess Patient Risk of Infection"
Dimitrios Kontoyiannis, M.D.
University of Texas M. D. Anderson Cancer Center

Genetics

"Roles of microRNA in familial chronic lymphocytic leukemia"
George Calin, M.D., Ph.D.
Ohio State University

"A study of the poor prognostic genomic alterations affecting 11q and 17p in CLL using CGH arrays"
Claire Dearden, M.D.
Royal Marsden Hospital/Institute of Cancer Research

"Epigenetic and therapeutic profiling of chronic lymphocytic leukemia"
Guillermo Garcia-Manero, M.D.
University of Texas M. D. Anderson Cancer Center

"Dissecting CLL heterogeneity by proteomic analysis"
Paolo Ghia, M.D., Ph.D.
Instituto Scientifico San Raffaele (Italy)

Immunology

"Targeting CLL antigens after stem cell transplantation"
John Gribben, M.D., DSc.
Barts Cancer Center of Excellence/ The London School of Medicine (UK)

Therapy/Prognostic

"Targeting ZAP-70 Tyrosine Kinase in Chronic Lymphocytic Leukemia"
Januario Castro, M.D.
University of California- San Diego

"Development of Glycolycin as a novel therapeutic"
Peng Huang, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center

2004 Grants:

Biology

"Characterization of the Proliferating Compartment in B-CLL Patients and in Healthy Aging Subjects"
Nicholas Chiorazzi, M.D.
North Shore-Long Island Jewish Research Institute

Therapy/Prognostic

"Validation of Prognostic Biomarkers in CLL"
Lynne Abruzzo, M.D., Ph.D.
University of Texas M.D. Anderson Cancer Center

"Transcription Inhibition to Target CLL"
Varsha Gandhi, Ph.D.
University of Texas M. D. Anderson Cancer Center

"A Phase I/II Study of Oral green Tea Extract in Asymptomatic Rai Stage 0-II Patients with Chronic Lymphocytic Leukemia"
Neil Kay, M.D
Mayo Clinic

"Immunotherapy with ISF35-Transduced Autologous CLL B Cells"
William Wierda, M.D., Ph.D.
University of Texas M. D. Anderson Cancer Center

RESEARCH NEWS

Read CLL Research Momentum for updates on funded projects.

• Fall 2007
• Spring 2007
• Fall 2006